摘要
乙型肝炎人免疫球蛋白(HBIG)是含有高效价乙型肝炎表面抗体(HBs Ab)的多克隆球蛋白制剂,其含量占蛋白质总量的96%以上。静脉输注后即刻达到高峰,能与乙肝病毒颗粒外壳上的乙型肝炎表面抗原(HBs Ag)特异性结合发生抗原抗体反应,从而使病毒失去对细胞的侵袭能力,它与拉米夫定联合应用是公认的预防肝移植术后HBV再感染的有效的常规治疗方法。但是,一旦停止HBIG用药,由于拉米夫定存在耐药性问题,HBV再感染率会升高。为此,国内外在HBIG预防肝移植术后HBV再感染长期效果方面做了大量研究工作,并取得了一些进展,现作一简要综述。
The hepatitis B immunoglobulin（ HBIG） is a preparation of polyclonal antibodies containing high titer hepatitis B surface antibody（ HBs Ab）,which exceeds more than 96% of total protein of in the preparation. The antibodies immediately reach to a maximal level after intravenous injection of HBIG. They can specifically bind to hepatitis B surface antigen（ HBs Ag） on hepatitis B virus（ HBV） so as to prevention of HBV infection,the treatment combined with lamivudine provides a conventional and effective therapy for HBV after liver transplantation. But once HBIG administration is stopped and due to lamivudine resistance,HBV reinfection rates will rise again. The review is about the progress on long-term prophylaxis protocol for HBV reinfection after liver transplantation by HBIG treatment.
出处
《微生物学免疫学进展》
2016年第2期89-92,共4页
Progress In Microbiology and Immunology
基金
深圳市重大产业技术攻关计划(ZD201010210078A)
关键词
乙型肝炎人免疫球蛋白
肝移植
HBV再感染
Hepatitis B immunoglobulin（HBIG）
Liver transplantation
Hepatitis B virus reinfection
